In view of this widely accepted “glio-centric” view of cerebral KP metabolism (cf. Figure 1), the failure of PLX5622 treatment to affect cerebral KMO activity, 3-HK and KYNA levels in healthy mice as well as in a mouse model of HD showing microglial activation, was unexpected and difficult to interpret. The gene discussed is KMO; the disease is Huntington disease.